Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

Executive Summary

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.

You may also be interested in...



MHRA’s Rawlins Plans British Version Of FDA’s Reg Science Centers

The head of UK agency wants Britain to get its own version of the FDA’s Centers of Excellence in Regulatory Science and Innovation network to promote collaborations between it and academia to advance regulatory science through research, education, and scientific exchanges.

MHRA’s Rawlins Says New Approach Needed For Clinical Trials

The chairman of Britain’s regulator the MHRA says clinical trials need more adaptive designs using smaller patient numbers if drug development costs are to be cut and innovative therapies made more accessible more quickly.

Europe’s Biotechs Want Flexibility When Seeking Scientific Advice

Biotechs and smaller companies have called for more flexibility and informal dialogue when seeking scientific advice from Europe’s regulators and HTA bodies on the development of their investigational medicines, says a joint survey by EuropaBio and the Deerfield Institute.

Related Content

Topics

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel